What is enGene Therapeutics Inc. Warrants's earnings per share (EPS)?

enGene Therapeutics Inc. Warrants (ENGNW) reported diluted earnings per share of $2.29 for fiscal year 2025. This represents a 56.8% change compared to the previous fiscal year. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

enGene Therapeutics Inc. Warrants (ENGNW) Financials

ENGNW

FY2025 annual

Net Income -$117.3M -112.7% YoY

EPS (Diluted) $2.29 +56.8% YoY

Free Cash Flow -$100.7M -104.7% YoY

Operating Cash Flow -$99.2M -105.5% YoY

Source SEC Filings (10-K/10-Q) Latest period Q3 FY2026, ended Jul 31, 2026 Reported Sep 8, 2026 Currency USD FYE October

Newest figures come from the 10-Q for Q3 FY2026, filed Sep 8, 2026. Each column of the statement tables below links to the filing it was taken from, and every filing is listed on the ENGNW SEC filings page.

This page shows enGene Therapeutics Inc. Warrants (ENGNW) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 4 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Rhea AI ENGNW FY2025 2026-09-08

Development spending drives enGene’s profile: no reported revenue, widening losses, and financing replacing operating cash generation.

FY2024 paired operating cash outflow of $48.3M with financing inflow of $265.7M, a funding pattern that more than replenished internal cash use. By FY2025, operating cash outflow had reached $99.2M while financing inflow was only $1.5M, leaving far less financing to offset operating needs.

With no reported revenue, the business remains in a development-stage operating model: FY2025 R&D of $94.5M was about 3.3x SG&A of $28.7M. That cost mix indicates the widening loss reflects heavier development investment rather than sales economics or gross-margin performance.

The balance sheet remains equity-funded rather than debt-funded: debt-to-equity was 0.3x and liabilities were $53.8M in FY2025. Yet the current ratio fell from 16.9x in FY2024 to 6.3x in FY2025, showing that short-term coverage narrowed as operating cash use accelerated.

Financial Health Signals

Financial health score not available

enGene Therapeutics Inc. Warrants does not currently provide enough eligible data for a peer-relative financial health score, so none is published. The signals and metrics below are current.

Piotroski F-Score Partial

1/6

enGene Therapeutics Inc. Warrants passes 1 of 6 computable financial strength tests (3 of the nine could not be computed from available data). 1 of 4 profitability signals pass, no leverage/liquidity signals pass (rising debt, declining liquidity, or share dilution).

Earnings Quality No Cash Backing

N/A

enGene Therapeutics Inc. Warrants reported a net loss of $117.3M while operations used $99.2M of cash. With neither figure positive, the ratio between the two carries no quality signal.

Interest Coverage At Risk

N/A

enGene Therapeutics Inc. Warrants reported an operating loss of $123.2M against $3.0M in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations.

Key Financial Metrics

Export CSV

Earnings & Revenue

EBITDA

-$33.9M

YoY-13.6%

QoQ-6.8%

enGene Therapeutics Inc. Warrants's EBITDA was -$33.9M in Q3 2026, measuring earnings before interest, taxes, depreciation, and amortization. This represents a decrease of 13.6% from the same quarter a year earlier. Against the prior quarter it is down 6.8%.

Net Income

-$32.5M

YoY-12.1%

QoQ-7.5%

enGene Therapeutics Inc. Warrants reported -$32.5M in net income in Q3 2026. This represents a decrease of 12.1% from the same quarter a year earlier. Against the prior quarter it is down 7.5%.

EPS (Diluted)

-$0.47

YoY+17.5%

QoQ-9.3%

enGene Therapeutics Inc. Warrants earned -$0.47 per diluted share (EPS) in Q3 2026. This represents an increase of 17.5% from the same quarter a year earlier. Against the prior quarter it is down 9.3%.

Revenue

Not reported for Q3 2026.

Cash & Balance Sheet

Free Cash Flow

-$18.9M

YoY+28.1%

QoQ+38.1%

enGene Therapeutics Inc. Warrants recorded an outflow of $18.9M in free cash flow in Q3 2026, representing a cash shortfall after capex. This represents an increase of 28.1% from the same quarter a year earlier. Against the prior quarter it is up 38.1%.

Cash & Debt

$41.0M

YoY+25.8%

QoQ+37.5%

enGene Therapeutics Inc. Warrants held $41.0M in cash as of Q3 2026; long-term debt is not reported for that period.

Shares Outstanding

67M

YoY+30.9%

QoQ0.0%

enGene Therapeutics Inc. Warrants had 67M shares outstanding in Q3 2026. This represents an increase of 30.9% from the same quarter a year earlier. It is unchanged from the prior quarter.

Dividends Per Share

Not reported for Q3 2026.

Margins & Returns

Return on Equity

-14.1%

YoY+0.3pp

QoQ-2.3pp

enGene Therapeutics Inc. Warrants's ROE was -14.1% in Q3 2026, measuring profit generated per dollar of shareholder equity. This is up 0.3 percentage points from the same quarter a year earlier. Against the prior quarter it is down 2.3 percentage points.

Gross Margin

Not reported for Q3 2026.

Operating Margin

Not reported for Q3 2026.

Net Margin

Not reported for Q3 2026.

Capital Allocation

R&D Spending

$20.1M

YoY-11.0%

QoQ-9.5%

enGene Therapeutics Inc. Warrants invested $20.1M in research and development in Q3 2026. This represents a decrease of 11.0% from the same quarter a year earlier. Against the prior quarter it is down 9.5%.

Capital Expenditures

YoY-100.0%

QoQ-100.0%

enGene Therapeutics Inc. Warrants reported no capital expenditure in Q3 2026. This represents a decrease of 100.0% from the same quarter a year earlier. Against the prior quarter it is down 100.0%.

Share Buybacks

Not reported for Q3 2026.

ENGNW Income Statement

Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

ENGNW quarterly income statement

Metric	TTM	FY2510-K	FY2410-K	FY2310-K	FY2210-K
R&D Expenses	N/A	$94.5M+146.6%	$38.3M+132.8%	$16.5M+6.4%	$15.5M
SG&A Expenses	N/A	$28.7M+19.6%	$24.0M+149.8%	$9.6M+142.5%	$4.0M
Operating Income	N/A	-$123.2M-97.7%	-$62.3M-139.1%	-$26.1M-34.1%	-$19.4M
EBITDA	N/A	-$122.7M-97.9%	-$62.0M-139.7%	-$25.9M-34.5%	-$19.2M
Interest Expense	N/A	$3.0M+7.0%	$2.8M-43.5%	$5.0M+248.1%	$1.4M
Income Tax	N/A	$0+100.0%	-$19K-211.8%	$17K-22.7%	$22K
Net Income	N/A	-$117.3M-112.7%	-$55.1M+44.8%	-$99.9M-308.5%	-$24.5M
EPS (Basic)	N/A	$2.29+56.8%	$1.46-99.0%	$151.22+241.4%	$44.30
EPS (Diluted)	$0.27	$2.29+56.8%	$1.46	$151.22	$44.30
Diluted Shares (Avg)	N/A	51M+35.3%	38M	692,609	655,153

Metric	Q3'2610-Q	Q2'2610-Q	Q1'2610-Q	Q4'2510-Q	Q3'2510-Q	Q2'2510-Q	Q1'2510-Q	Q4'2410-K
R&D Expenses	$20.1M-11.0%	$22.2M+9.8%	$22.3M+11.4%	N/A	$22.6M+95.5%	$20.2M+105.1%	$20.0M+254.3%	N/A
SG&A Expenses	$13.9M+88.9%	$9.8M+41.3%	$8.9M+34.5%	N/A	$7.4M+41.5%	$6.9M-7.2%	$6.6M+29.3%	N/A
Operating Income	-$34.0M-13.6%	-$32.0M-17.9%	-$31.2M-17.2%	N/A	-$29.9M-78.7%	-$27.1M-56.7%	-$26.6M-147.0%	N/A
EBITDA	-$33.9M-13.6%	-$31.8M-17.6%	-$31.0M-16.9%	N/A	-$29.8M-79.2%	-$27.0M-57.0%	-$26.5M-147.9%	N/A
Interest Expense	$843K+11.2%	$745K+1.5%	$732K-2.7%	N/A	$758K+0.9%	$734K+0.8%	$752K+33.6%	N/A
Income Tax	$0-100.0%	$0-100.0%	$0-100.0%	N/A	$239K+924.1%	$240K+1042.9%	$18K+160.0%	N/A
Net Income	-$32.5M-12.1%	-$30.2M-17.1%	-$29.8M-20.9%	N/A	-$29.0M-104.9%	-$25.8M-72.3%	-$24.6M-129.8%	N/A
EPS (Basic)	-$0.47+17.5%	-$0.43+15.7%	$0.44-8.3%	$0.73+114.7%	-$0.57-278.1%	-$0.51-234.2%	$0.48+4.3%	$0.34-99.7%
EPS (Diluted)	-$0.47+17.5%	-$0.43+15.7%	$0.44-8.3%	$0.73+114.7%	-$0.57-278.1%	-$0.51-234.2%	$0.48+4.3%	$0.34
Diluted Shares (Avg)	70M+36.5%	70M+36.7%	67M+31.9%	N/A	51M+15.7%	51M+29.3%	51M+119.7%	N/A

Not reported in any period shown, so not listed: Revenue, Cost of Revenue, Gross Profit.

ENGNW Balance Sheet

ENGNW quarterly balance sheet

Metric	FY2510-K	FY2410-K	FY2310-K	FY2210-K
Total Assets	$221.5M-28.8%	$311.2M+257.8%	$87.0M+263.7%	$23.9M
Current Assets	$201.4M-18.6%	$247.4M+189.5%	$85.4M+278.3%	$22.6M
Cash & Equivalents	$50.2M-71.0%	$173.0M+112.2%	$81.5M+298.9%	$20.4M
Short-Term Investments	$143.6M+119.8%	$65.3M	$0	$0
Long-Term Investments	$8.5M-85.7%	$59.5M	$0	$0
Total Liabilities	$53.8M+39.4%	$38.6M+166.4%	$14.5M-85.6%	$100.5M
Current Liabilities	$32.0M+118.1%	$14.7M+178.9%	$5.3M+3.0%	$5.1M
Non-Current Liabilities	$21.8M-8.9%	$23.9M+159.3%	$9.2M-90.3%	$95.4M
Total Equity	$167.7M-38.5%	$272.6M+276.1%	$72.5M+194.6%	-$76.6M
Retained Earnings	-$372.0M-46.0%	-$254.7M-27.6%	-$199.6M-100.2%	-$99.7M

Metric	Q3'2610-Q	Q2'2610-Q	Q1'2610-Q	Q4'2510-Q	Q3'2510-Q	Q2'2510-Q	Q1'2510-Q	Q4'2410-K
Total Assets	$288.3M+17.4%	$307.5M+15.3%	$337.1M+17.9%	$221.5M-28.8%	$245.6M-8.0%	$266.7M-2.5%	$285.9M+206.1%	$311.2M+257.8%
Current Assets	$277.9M+31.5%	$270.0M+18.4%	$289.2M+30.1%	$201.4M-18.6%	$211.3M-19.6%	$228.0M-15.4%	$222.3M+148.2%	$247.4M+189.5%
Cash & Equivalents	$41.0M+25.8%	$29.8M-48.2%	$36.6M-41.3%	$50.2M-71.0%	$32.6M-87.3%	$57.5M-78.3%	$62.3M-27.2%	$173.0M+112.2%
Short-Term Investments	$225.3M+33.1%	$228.6M+43.0%	$239.3M+58.0%	$143.6M+119.8%	$169.3M	$159.8M	$151.5M	$65.3M
Long-Term Investments	$0-100.0%	$26.7M-21.7%	$36.6M-37.9%	$8.5M-85.7%	$23.0M	$34.1M	$59.0M	$59.5M
Total Liabilities	$58.0M+29.3%	$52.4M+33.0%	$55.6M+54.4%	$53.8M+39.4%	$44.9M+22.8%	$39.4M+28.8%	$36.0M+15.9%	$38.6M+166.4%
Current Liabilities	$27.2M+33.1%	$21.5M+19.4%	$24.6M+90.0%	$32.0M+118.1%	$20.4M+51.9%	$18.0M+185.8%	$13.0M+87.6%	$14.7M+178.9%
Non-Current Liabilities	$30.8M+26.1%	$30.9M+44.5%	$31.0M+34.4%	$21.8M-8.9%	$24.4M+5.8%	$21.4M-12.0%	$23.0M-4.6%	$23.9M+159.3%
Total Equity	$230.3M+14.8%	$255.2M+12.3%	$281.5M+12.6%	$167.7M-38.5%	$200.7M-12.9%	$227.3M-6.5%	$249.9M+300.7%	$272.6M+276.1%
Retained Earnings	-$464.5M-39.0%	-$432.0M-41.6%	-$401.8M-43.8%	-$372.0M-46.0%	-$334.2M-39.6%	-$305.2M-35.5%	-$279.3M-32.8%	-$254.7M-27.6%

Not reported in any period shown, so not listed: Inventory, Accounts Receivable, Goodwill, Long-Term Debt.

ENGNW Cash Flow Statement

ENGNW quarterly cash flow statement

Metric	TTM	FY2510-K	FY2410-K	FY2310-K	FY2210-K
Operating Cash Flow	-$103.3M	-$99.2M-105.5%	-$48.3M-95.1%	-$24.7M-40.6%	-$17.6M
Depreciation & Amortization	N/A	$500K+66.7%	$300K+50.0%	$200K0.0%	$200K
Stock-Based Compensation	N/A	$9.6M+81.2%	$5.3M+54.3%	$3.5M+2874.1%	$116K
Capital Expenditures	$688K	$1.5M+60.5%	$925K+190.9%	$318K+107.8%	$153K
Free Cash Flow	-$104.0M	-$100.7M-104.7%	-$49.2M-96.3%	-$25.1M-41.2%	-$17.7M
Investing Cash Flow	-$32.0M	-$25.1M+80.0%	-$126.0M-39507.9%	-$318K-107.8%	-$153K
Financing Cash Flow	$143.7M	$1.5M-99.4%	$265.7M+208.4%	$86.1M+208.0%	$28.0M
Dividends Paid	N/A	N/A	N/A	$0	N/A

Metric	Q3'2610-Q	Q2'2610-Q	Q1'2610-Q	Q4'2510-Q	Q3'2510-Q	Q2'2510-Q	Q1'2510-Q	Q4'2410-K
Operating Cash Flow	-$18.9M+26.1%	-$30.5M-32.9%	-$28.9M-12.5%	-$25.0M-27.6%	-$25.6M-257.0%	-$22.9M-62.0%	-$25.7M-248.7%	-$19.6M-188.8%
Depreciation & Amortization	$100K0.0%	$200K+100.0%	$189K+85.3%	$200K+100.0%	$100K0.0%	$100K0.0%	$102K+27.5%	$100K+35.1%
Stock-Based Compensation	$7.8M+202.6%	$4.1M+56.4%	$2.8M+54.9%	N/A	$2.6M+76.8%	$2.6M+38.2%	$1.8M+521.6%	N/A
Capital Expenditures	$0-100.0%	$98K+117.8%	$153K-48.8%	$437K+83.6%	$704K+35100.0%	$45K-74.9%	$299K-40.9%	$238K+72.5%
Free Cash Flow	-$18.9M+28.1%	-$30.6M-33.1%	-$29.1M-11.8%	-$25.4M-28.2%	-$26.3M-266.7%	-$23.0M-60.3%	-$26.0M-230.1%	-$19.8M-186.5%
Investing Cash Flow	$30.1M+2084.3%	$23.6M+31.7%	-$126.3M-48.6%	$40.5M+132.3%	$1.4M+69050.0%	$17.9M+10126.3%	-$85.0M-16691.3%	-$125.3M-90672.5%
Financing Cash Flow	$23K+103.4%	$74K-62.8%	$141.7M+14165900.0%	$2.0M-96.7%	-$667K-1407.8%	$199K-99.9%	$1K-100.0%	$60.2M+18.3%

Not reported in any period shown, so not listed: Dividends Paid, Share Buybacks.

ENGNW Financial Ratios

Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

ENGNW quarterly financial ratios

Metric	FY2510-K	FY2410-K	FY2310-K	FY2210-K
Return on Equity	-69.9%-49.7pp	-20.2%+117.6pp	-137.8%	N/A
Return on Assets	-53.0%-35.2pp	-17.7%+97.2pp	-114.9%-12.6pp	-102.3%
Current Ratio	6.30-10.6x	16.87+0.6x	16.25+11.8x	4.42
Debt-to-Equity	0.32+0.2x	0.14-0.1x	0.20	N/A

Metric	Q3'2610-Q	Q2'2610-Q	Q1'2610-Q	Q4'2510-Q	Q3'2510-Q	Q2'2510-Q	Q1'2510-Q	Q4'2410-K
Return on Equity	-14.1%+0.3pp	-11.8%-0.5pp	-10.6%-0.7pp	N/A	-14.4%-8.3pp	-11.4%-5.2pp	-9.8%+7.3pp	N/A
Return on Assets	-11.3%+0.5pp	-9.8%-0.2pp	-8.8%-0.2pp	N/A	-11.8%-6.5pp	-9.7%-4.2pp	-8.6%+2.9pp	N/A
Current Ratio	10.21-0.1x	12.57-0.1x	11.75-5.4x	6.30-10.6x	10.34-9.2x	12.66-30.1x	17.16+4.2x	16.87+0.6x
Debt-to-Equity	0.250.0x	0.210.0x	0.20+0.1x	0.32+0.2x	0.22+0.1x	0.170.0x	0.14-0.4x	0.14-0.1x

Not reported in any period shown, so not listed: Gross Margin, Operating Margin, Net Margin, Asset Turnover, FCF Margin.

Similar Companies

Newest fiscal year on record for each company. The health score is the peer-relative Financial Health Score for that year; a dash means no score is published for it.

Company	Fiscal year	Revenue	Net income	Net margin	Market cap	Health score
enGene Therapeutics Inc. Warrants ENGNW	FY2025	N/A	-$117.3M	N/A	N/A	—
Aspire-Lakewood Holdings, Inc. Warrant ASBPW	FY2025	$6K	N/A	N/A	N/A	—
BriaCell Therapeutics Corp. Warrant BCTXW	FY2025	N/A	-$26.3M	N/A	N/A	—
BriaCell Therapeutics Corp. Warrant BCTXZ	FY2025	N/A	-$26.3M	N/A	N/A	—

Where enGene Therapeutics Inc. Warrants Ranks

Frequently Asked Questions

Is enGene Therapeutics Inc. Warrants profitable?

No, enGene Therapeutics Inc. Warrants (ENGNW) reported a net income of -$117.3M in fiscal year 2025.

What is enGene Therapeutics Inc. Warrants's EBITDA?

enGene Therapeutics Inc. Warrants (ENGNW) had EBITDA of -$122.7M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.

What is enGene Therapeutics Inc. Warrants's return on equity (ROE)?

enGene Therapeutics Inc. Warrants (ENGNW) has a return on equity of -69.9% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.

What is enGene Therapeutics Inc. Warrants's free cash flow?

enGene Therapeutics Inc. Warrants (ENGNW) recorded an outflow of $100.7M in free cash flow during fiscal year 2025. This represents a -104.7% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.

What is enGene Therapeutics Inc. Warrants's operating cash flow?

enGene Therapeutics Inc. Warrants (ENGNW) recorded an outflow of $99.2M in operating cash flow during fiscal year 2025, representing cash used by core business activities.

What are enGene Therapeutics Inc. Warrants's total assets?

enGene Therapeutics Inc. Warrants (ENGNW) had $221.5M in total assets as of fiscal year 2025, including both current and long-term assets.

What are enGene Therapeutics Inc. Warrants's capital expenditures?

enGene Therapeutics Inc. Warrants (ENGNW) invested $1.5M in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.

How much does enGene Therapeutics Inc. Warrants spend on research and development?

enGene Therapeutics Inc. Warrants (ENGNW) invested $94.5M in research and development during fiscal year 2025.

How many shares does enGene Therapeutics Inc. Warrants have outstanding?

enGene Therapeutics Inc. Warrants (ENGNW) had 67M shares outstanding as of fiscal year 2025.

What is enGene Therapeutics Inc. Warrants's current ratio?

enGene Therapeutics Inc. Warrants (ENGNW) had a current ratio of 6.30 as of fiscal year 2025, which is generally considered healthy.

What is enGene Therapeutics Inc. Warrants's debt-to-equity ratio?

enGene Therapeutics Inc. Warrants (ENGNW) had a debt-to-equity ratio of 0.32 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.

What is enGene Therapeutics Inc. Warrants's return on assets (ROA)?

enGene Therapeutics Inc. Warrants (ENGNW) had a return on assets of -53.0% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.

How does enGene Therapeutics Inc. Warrants's liquidity compare with its operating cash outflow?

At the end of fiscal year 2025, enGene Therapeutics Inc. Warrants (ENGNW) held $202.3M in cash, cash equivalents and investments, and reported an operating cash outflow of $99.2M over that year. Dividing the one by the other, the reported balance equals about 24 months of the outflow reported that year. This is arithmetic over figures already filed, not a projection: it assumes nothing about future spending, financing or operations.

What is enGene Therapeutics Inc. Warrants's Piotroski F-Score?

enGene Therapeutics Inc. Warrants (ENGNW) has a Piotroski F-Score of 1 out of 6 computable signals; 3 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Are enGene Therapeutics Inc. Warrants's earnings high quality?

enGene Therapeutics Inc. Warrants (ENGNW) reported a net loss of $117.3M while operations used $99.2M of cash. With neither figure positive, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.

Can enGene Therapeutics Inc. Warrants cover its interest payments?

enGene Therapeutics Inc. Warrants (ENGNW) reported an operating loss of $123.2M against $3.0M in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.